SOURCE-LINKED STUDY SUMMARY
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Abstract summarizedQuality not appraised
- What was studied
- This randomized trial tested the safety and metabolic effects of high-dose nicotinamide riboside in obese, insulin-resistant men.
- Who / model studied
- Forty sedentary men had BMI above 30 kg/m² and were 40–70 years old.
- Studied dose & schedule
- Participants received nicotinamide riboside 1000 mg twice daily or placebo for 12 weeks in a double-blind, parallel-group trial.
- What the study found
- NR did not improve clamp-measured insulin sensitivity, glucose production, glucose disposal, energy expenditure, lipolysis, lipid oxidation, or body composition.
- Limitations & context
- The study included only obese men. No serious NR-related adverse events occurred, but short-term safety does not establish metabolic efficacy.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1093/ajcn/nqy132